The $26 million hair growth injectable that started with a hairy mole — Amplifica's osteopontin discovery, the Phase 1 results, and what Eli Lilly's participation signals.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
0:00
|
7:06
From Root to Ritual by Laritelle Organic.
In brief: Amplifica Holdings Group closed an oversubscribed $26 million Series B financing on August 12, 2026 — with Eli Lilly and Company participating as a strategic investor. The company is clinical-stage, spun out of UC Irvine, and built on a discovery by Professor Maksim Plikus: senescent pigment cells in hairy moles produce osteopontin, a signalling molecule that reactivates dormant hair fol...
Read the full article: https://laritelleorganic.com/blogs/from-root-to-ritual/the-26-million-hair-growth-injectable-that-started-with-a-hairy-mole-amplificas-osteopontin-discovery-the-phase-1-results-and-what-eli-lillys-participation-signals
SPEAKER_00
In brief, Amplifica Holdings Group closed an oversubscribed $26 million Series B financing on August 12, 2026, with Eli Lilly and Company participating as a strategic investor. The company is clinical stage, spun out of UC Irvine and built on a discovery by Professor Maxim Plikis. Senescent pigment cells in hairy moles produce osteopontin, a signaling molecule that reactivates dormant hair follicle stem cells. Their lead injectable candidate, AMP 303, completed a phase 1 randomized controlled trial in September 2024, showing statistically significant increases in nonvellous hair count at 60 days, p0.001. This is early stage science with genuine biological coherence. Here is the complete honest picture. Where did the science come from? And what is the osteopontin discovery? The scientific origin of Amplifica is one of the more elegant stories in recent hair loss research. It begins not with a hair loss patient, but with a mole. While most people would see a hairy mole as a problem, Professor Maxim Plequis at the University of California Irvine had the unique ability to see this phenomenon as an opportunity. Although senescent, aging, and degraded pigment cells found in moles are typically seen as harmful as they accumulate in body tissues, plequis discovered a silver lining. The senescent pigment cells in hairy moles generate abundant osteopontin, a signaling molecule that prompts dormant hair follicles to activate their stem cells and foster hair growth. The observa. Chin is this. Moles grow unusually dense, coarse, dark hair. The pigment cells in moles are senescent, biologically aged, yet they are producing a molecular signal that drives exceptional follicle activity in the surrounding skin. That signal is osteopontin. The hair follicles of people with androgenetic alopecia are mostly intact, they are just dormant. Plecus and the Amplifica team plan to apply these activating signaling molecules to the scalp to prompt dormant follicles to produce new hair, effectively reverse engineering nature to recreate a natural phenomenon. This is the fundamental premise that makes Amplifica's approach mechanistically interesting. Most existing hair loss treatments work by slowing the miniaturization of follicles or improving the conditions for growth. Currently, marketed products are primarily intended to slow or prevent further hair loss. Amplifica's injectable candidates are designed to do something categorically different. Reactivate the follicle stem cells that have become quiescent in ag, converting miniaturized vellus hairs back into terminal hairs rather than simply slowing further loss. What did the phase one trial of AMP 303 find? One first inhuman, randomized, double-blind, placebo-controlled, multicenter phase one trial has been completed, with results announced in September 2024 and presented at the Society for Investigative Dermatology annual meeting in May 2025. Male participants aged 18, 45 with androgenetic alopecia were stratified, ed by duration of hair loss, 3, 5 years versus 10 years, and received AMP 303 on one side of the scalp and placebo on the other. A statistically significant percentage of participants showed greater than 15% increase in non-velous hair count at 60 days post-treatment, P0.001, compared to placebo. The design detail worth noting each participant served as their own control, AMP 303 on one side of the scalp, placebo on the other. This within subject design eliminates the genetic and environmental variability that plagues between subject hair trials, making the P0.001 result more meaningful than it would be in a parallel group design of the same sample size. The reported vellus to terminal conversion, miniaturized hairs converting back to thicker, pigmented terminal hairs, would represent a meaningful reversal of AGA pathology if confirmed at scale. This is the biological claim that distinguishes AMP 303 from minoxidil and phenasteride, not slowing miniaturization but reversing it, the honest limitation. Phase 1 is primarily a safety trial. Efficacy signals at phase 1 are encouraging, but the definitive evidence comes from phase 2 and phase 3, larger, longer, with primary efficacy endpoints. The precise molecular target has not yet been described publicly. Amplifica has not disclosed the exact identity of the signaling molecules in AMP303, describing them only as nature-inspired biological signaling molecules. The 60-day time point is also short for assessing hair cycle F. ECTs, which typically require 6-12 months for meaningful assessment, p0.001, statistical significance of AMP 303 Phase 1 results. 15% increase in non-velous hair count at 60 days versus placebo. Within subject design, each participant their own control strengthens the result. Eli Lilly strategic investor in the $26 million Series B, the same company that markets for Zenyo, breast cancer, Munjaro, GLP1, and Kisunla, Alzheimer's. A strategic pharma investor signals clinical development credibility. $37.8 million total disclosed funding after Series B, $11.8 million Series A, October 2022, plus $26 million, Series B, August 2026. Over-subscribed round indicates strong investor demand beyond the target raise. What does Eli Lilly's participation actually signal? Eli Lilly, investing as a strategic participant, not just a financial investor, is the detail that most distinguishes this financing from a typical biotech Series B. The participation of Eli Lilly adds a strategic pharmaceutical investor to the financing, alongside institutional and existing backers. Amplifica did not disclose any development, licensing, or commercialization partnership with Lilly in connection with the investment. Strategic pharmaceutical investment without a disclosed partnership is a standard pattern in early stage biotech. Large pharma takes a minority position to monitor a clinical program with licensing or acquisition optionality if later stage results are strong. Eli Lilly's dermatology and endocrinology portfolios make